Mustang Bio surges as co to start its own cancer therapy trial
Mustang Bio Inc reports results for the quarter ended in December - Earnings Summary
Mustang Bio Inc expected to post a loss of 19cents a share - Earnings Preview
Brief: Mustang Bio Completes A $75 Mln Debt Financing With Runway Growth Capital
Brief: Mustang Bio Provides An Update On Its Ind Application For Mb-207, A Lentiviral Gene Therapy For Treatment Of X-Linked Severe Combined Immunodeficiency (“Xscid”) In Previously Transplanted Patients
Cell, gene therapy companies pressured by supply and manufacturing issues -BTIG
Brief: Mustang Bio Added To Nasdaq Biotechnology Index
Brief: Mustang Bio Announces Updated Interim Phase 1/2 Data For Mb-106 In Patients With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma And Chronic Lymphocytic Leukemia
Mustang Bio Inc reports results for the quarter ended in September - Earnings Summary
Brief: Mustang Bio Reports Q3 Loss Per Share Of $0.19
Brief: Mustang Bio Announces Exclusive Worldwide License Agreement with Leiden University Medical Centre
Brief: Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy For Treatment Of B-Cell Non-Hodgkin Lymphomas
Mustang Bio Inc reports results for the quarter ended in June - Earnings Summary
Brief: Mustang Bio Q2 Loss Per Share $0.16
Mustang Bio Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Mustang Bio Inc Collaborates with Mayo Clinic on Novel CAR T Technology
Mustang Bio Inc expected to post a loss of 20 cents a share - Earnings Preview
Mustang Bio Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Mustang Bio Receives European Medicines Agency Prime Designation For Mb-107 To Treat X-Linked Severe Combined Immunodeficiency In Newly Diagnosed Infants